Advertisement

Topics

FDA authorizes marketing of test to aid in diagnoses of serious cancers

16:36 EDT 29 Jun 2017 | News-Medical.net

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).

Original Article: FDA authorizes marketing of test to aid in diagnoses of serious cancers

NEXT ARTICLE

More From BioPortfolio on "FDA authorizes marketing of test to aid in diagnoses of serious cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...